Loading cancer entity…
Loading cancer entity…
Clinical trials
181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (27)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07839858 | A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment of Second-line Polycythemia Vera in France(VeRavie) | completed | — | 237 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT01831635 | Myeloproliferative Neoplasms: an In-depth Case-control Study(MOSAICC) | completed | — | 234 | Queen's University, BelfastOTHER |
| 1 |
| Sep 11, 2026 |
| clinicaltrials |
| NCT06752941 | LOW-PV Continuation(CONT-LOW-PV) | completed | — | 36 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETSOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT02493530 | TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea | completed | Phase 1 | 60 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05558696 | A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004) | completed | Phase 2 | 20 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)INDUSTRY | 3 | May 7, 2026 | clinicaltrials |
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT01787487 | Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm | completed | Phase 2 | 121 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT00255346 | Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | completed | Phase 2 | 68 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT01760655 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies | completed | Phase 2 | 62 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT04182100 | Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply | completed | Phase 2 | 29 | PharmaEssentia Japan K.K.INDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04057040 | Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE) | completed | Phase 2 | 70 | Protagonist Therapeutics, Inc.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT00588991 | Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06002490 | A Study to Evaluate P1101 in Japanese PV Patients | completed | Phase 3 | 21 | PharmaEssentia Japan K.K.INDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT03003325 | The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV(Low-PV) | completed | Phase 2 | 127 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06134102 | Clinical and Laboratory Characteristics of Polycythemia Vera(PV-ARC) | completed | — | 1,150 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT04243122 | Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients(AIRPORT-MPN) | completed | Phase 2 | 44 | Ottawa Hospital Research InstituteOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05853445 | A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera(PAVE) | completed | — | 467 | Novartis PharmaceuticalsINDUSTRY | 1 | May 6, 2024 | clinicaltrials |
| NCT06371573 | Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms | completed | — | 45 | Federico II UniversityOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT01588015 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04767802 | PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit(PACIFIC) | completed | Phase 2 | 20 | Protagonist Therapeutics, Inc.INDUSTRY | 2 | Mar 18, 2024 | clinicaltrials |
| NCT01816256 | Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms | completed | N/A | 102 | University Health Network, TorontoOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT04051307 | Dual Vaccine Trial in Myeloproliferative Neoplasms | completed | Phase 1 / Phase 2 | 9 | Inge Marie SvaneOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT02124746 | Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia | completed | Phase 2 | 87 | Sierra Oncology LLC - a GSK companyINDUSTRY | 5 | Jun 18, 2023 | clinicaltrials |
| NCT02098161 | LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis | completed | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT03895112 | MPN-RC 118 AVID200 in Myelofibrosis | completed | Phase 1 | 21 | John MascarenhasOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT02556931 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | completed | Phase 2 | 117 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT05421104 | Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea. | completed | — | 1,576 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 5, 2022 | clinicaltrials |
| NCT01387763 | A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms(DALIAH) | completed | Phase 3 | 202 | Thomas Stauffer LarsenOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT01423851 | Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF | completed | Phase 1 / Phase 2 | 77 | NS Pharma, Inc.INDUSTRY | 1 | Mar 9, 2022 | clinicaltrials |
| NCT01981850 | A Phase 2 Study of RO7490677 In Participants With Myelofibrosis | completed | Phase 2 | 125 | Hoffmann-La RocheINDUSTRY | 8 | Jan 5, 2022 | clinicaltrials |
| NCT00038675 | Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate | completed | N/A | 125 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT02038036 | Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.(RESPONSE-2) | completed | Phase 3 | 149 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 20, 2021 | clinicaltrials |
| NCT03065400 | PD-1 Inhibition in Advanced Myeloproliferative Neoplasms | completed | Phase 2 | 10 | John MascarenhasOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT02218047 | AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.(CONTI-PV) | completed | Phase 3 | 170 | AOP Orphan Pharmaceuticals AGINDUSTRY | 12 | Jun 1, 2021 | clinicaltrials |
| NCT02912884 | Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure(MPNClot) | completed | — | 80 | Dr Yan BeauverdOTHER | 2 | Nov 10, 2020 | clinicaltrials |
| NCT02823184 | Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms(PhiNESS) | completed | — | 148 | University Hospital, BordeauxOTHER | 1 | Jun 19, 2020 | clinicaltrials |
| NCT01787552 | A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | completed | Phase 1 / Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 11 | Apr 15, 2020 | clinicaltrials |
| NCT03907436 | The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase(NUTRIENT) | completed | N/A | 30 | University of California, IrvineOTHER | 1 | Mar 24, 2020 | clinicaltrials |
| NCT00397813 | Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders | completed | Phase 2 | 77 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT03745378 | Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)(MPN-K) | completed | — | 1,881 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETSOTHER | 6 | Dec 6, 2019 | clinicaltrials |
| NCT00928707 | Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera(PV) | completed | Phase 2 | 45 | ItalfarmacoINDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
| NCT02129101 | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | completed | Phase 1 | 63 | Mayo ClinicOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT00715247 | Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes | completed | — | 726 | University of UtahOTHER | 1 | Oct 15, 2019 | clinicaltrials |
| NCT01529827 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 94 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT02407080 | Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia | completed | Phase 1 | 13 | John MascarenhasOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01901432 | A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera | completed | Phase 1 / Phase 2 | 48 | ItalfarmacoINDUSTRY | 5 | Jul 30, 2019 | clinicaltrials |
| NCT02292446 | Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. | completed | Phase 3 | 161 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 18, 2019 | clinicaltrials |
| NCT00666549 | Research Tissue Bank | completed | — | 963 | Icahn School of Medicine at Mount SinaiOTHER | 2 | Jul 5, 2019 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials